Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chondroitin Sulfate in Knee Osteoarthritis (MOTION)
NCT05632783Phase 3Withdrawn
- Sponsor
- IBSA Group
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Biomacromolecule, Polysaccharide, GAG (Glycosaminoglycan)
01
Overview
Phase 3, randomised, double-blind trial of chondroitin sulfate in knee osteoarthritis (OA), sponsored by IBSA Group. Primary endpoint: Change from Baseline to Week 24 in the weekly mean of the average daily pain in the index knee. Planned start Dec 2023; status: withdrawn.
02
Drugs
chondroitin sulfate
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05632783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05632783.